Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 195,579	$ 55,516
Short-term investments – available for sale	767,397	306,563
Prepaid clinical trial and preclinical study costs	2,716	2,624
Prepaid expenses and other current assets	643	2,522
Total current assets	966,335	367,225
Right-of-use assets	1,052	1,126
Deferred financing costs	98	106
Deposits	33	33
Total assets	967,518	368,490
Current liabilities:
Accounts payable	5,225	7,512
Other accrued liabilities	27,220	11,299
Lease liability, current	329	324
Total current liabilities	32,774	19,135
Lease liability, net of current portion	852	936
Total long-term liabilities	852	936
Total liabilities	33,626	20,071
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 110,228,869 shares issued and outstanding at March 31, 2024 and 100,113,770 shares issued and outstanding at December 31, 2023	1	1
Treasury stock at cost, no shares at March 31, 2024 and 2,193,251 shares at December 31, 2023	0	(6,795)
Additional paid-in capital	1,340,789	733,546
Accumulated deficit	(405,299)	(377,944)
Accumulated other comprehensive loss	(1,599)	(389)
Total stockholders’ equity	933,892	348,419
Total liabilities and stockholders’ equity	$ 967,518	$ 368,490